45 results about "Taurolidine" patented technology

Treating of localized bacterial infection, comprising locally applying Taurolidine to the infection. A device for insertion into the body, the device comprising Taurolidine to render the device infection resistant. A medication for treating bacterial infections, comprising Taurolidine carried by one of: gels, liquid, thixotropic gels, colloidal mixtures, dispensal suspensions, injectable polymers, or a microparticle. A method for treating blood, comprising: removing blood from the body; treating the blood with Taurolidine; and returning the treated blood.

An antiseptic preparation is provided for the production of wound dressings or bandages. The preparation includes at least one alginate and at least one antiseptically active substance selected from the group biguanide derivatives, octenidine and taurolidine. Processes for the production of the antiseptic preparations, and the use thereof, are also provided.

The invention provides a quality detection method for Taurolidine. The method uses thin-layer chromatography, gas phase chromatography and titering process to detect the quality of the Taurolidiene. The quality detection method for Taurolidine has the advantages of rapidness, accuracy, convenient operation and excellent reproduction quality, and ensures the product quality of the Taurolidine.

Compositions and methods are provided for preventing formation of thrombosis on a liquid-contacting surface of a liquid delivery system, such as a port, catheter or port-catheter system. The liquid delivery system is connected to a patient for delivery of a liquid to the patient. The method involves contacting the surface with a thrombosis-preventing liquid containing taurolidine, taurultam or a mixture thereof, the thrombosis-preventing liquid further containing an anticoagulant agent. In an alternative embodiment, the liquid-contacting surface of the delivery system is contacted with a solution containing an anticoagulant agent, and thereafter contacted with a solution containing taurolidine, taurultam or a mixture thereof.

Treatment of a skin disease selected from acne, rosacea, atopical dermatitis, and various ulcers, by topically applying a suitable pharmaceutical composition containing an effective amount of taurolidine, taurultam or a mixture containing both.

Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.

The invention provides a synthetic method for taurolidine and a medicinal preparation thereof. The method comprises the preparing steps: adopting cysteamine hydrochloride as raw material to carry out the reaction of chloridization, azide and hydrogenization, preparing the target product taurolidine by condensation reaction with formaldehyde. The synthetic route avoids the shortages of multistep process of the original synthetic route which consumes large amount of and complex chemical materials and is easy to cause side effect. By adopting the technique of the invention, the prepared taurolidine has higher purity, and the preparation made is more stable and has exacter healing effect.

It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5.

A composition comprising: hydrolysable taurolidine; and a hydrolysable lipophilic excipient; wherein the hydrolysable taurolidine is contained within the hydrolysable lipophilic excipient.

An antimicrobial suture comprising a filament and taurolidine.

The invention relates to an application of taurolidine in preparation of anti-HIV virus drugs, and relates to the technical field of medicines. The new application of taurolidine is discovered for thefirst time, namely the application of taurolidine in inhibition of HIV virus or in preparation of HIV virus drugs. The safety of taurolidine to a human body is detected by clinical practice, the obvious drug effect of taurolidine on HIV virus is discovered, powerful theoretical basis and practical basis are provided for anti-HIV virus, and the taurolidine has development value and popularizationsignificance. According to the application, the inactivation effect of taurolidine on human immunodeficiency virus HIV is detected on a cellular level, and the inactivation efficiency is about 73%. The invention provides a new way for treatment of AIDS.

The invention provides an application of taurolidine in virus resistance. Specifically, the invention provides use of the taurolidine or a derivative thereof, a prodrug, a solvate or a pharmaceutically acceptable salt thereof, or a composition containing the taurolidine or the derivative thereof, the prodrug, the solvate or the pharmaceutically acceptable salt thereof in preparation of antiviral drugs. Research results show that the taurolidine can significantly inhibit influenza virus and coronavirus at a cellular level. In addition, in-vivo experiments prove that taurolidine has a remarkable protection effect on lungs and can prolong the survival time of mice infected with influenza viruses or SARS-CoV-2 viruses. Therefore, the taurolidine can be used for preventing and treating lung diseases caused by the influenza virus or the coronavirus. The research result of the application expands the efficacy range of the taurolidine, and provides a research basis and opens up a new direction for research and development of drugs for preventing or treating pulmonary infection caused by the viruses.

Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.

Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.

Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. This invention relates to the use of taurolidine for the treatment of neuroblastoma in juvenile mammals.